| Drug Name |
Alirocumab |
| Drug ID |
BADD_D00072 |
| Description |
Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood. |
| Indications and Usage |
Alirocumab is an antibody eliciting proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor activity that is indicated for:
(i) use in reducing the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease [F4591], and/or
(ii) use as an adjunct to diet or use alone or in combination with other lipid-lowering therapies (statins, ezetimibe, for example) for the treatment of adults with primary hyperlipidemia (including heterozygous familial hypercholesterolemia) to reduce low-density lipoprotein cholesterol (LDL-C) levels in the body [F4591]. |
| Marketing Status |
approved |
| ATC Code |
C10AX14 |
| DrugBank ID |
DB09302
|
| KEGG ID |
D10335
|
| MeSH ID |
C571059
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
D00GNI
|
| NDC Product Code |
61755-020; 61755-021; 0024-5903; 72733-5901; 0024-5901; 0024-5904; 72733-5902; 0024-5902 |
| UNII |
PP0SHH6V16
|
| Synonyms |
alirocumab | SAR236553 | SAR-236553 | REGN-727 | monoclonal antibody REGN727 | REGN727 monoclonal antibody | REGN727 | praluent |
